• LAST PRICE
    13.3599
  • TODAY'S CHANGE (%)
    Trending Down-0.4501 (-3.2592%)
  • Bid / Lots
    13.3500/ 1
  • Ask / Lots
    13.3600/ 4
  • Open / Previous Close
    13.7700 / 13.8100
  • Day Range
    Low 13.2000
    High 14.8400
  • 52 Week Range
    Low 2.0900
    High 14.8400
  • Volume
    7,012,868
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 13.81
TimeVolumeALT
09:32 ET19703113.6695
09:33 ET10980213.7
09:35 ET10194413.91
09:37 ET4144713.75
09:39 ET5358613.8797
09:42 ET23823114.2
09:44 ET16970714.2
09:46 ET16119914.282
09:48 ET15775014.175
09:50 ET9771813.95
09:51 ET12455013.87
09:53 ET12690013.96
09:55 ET10764213.94
09:57 ET8236913.8841
10:00 ET4386613.9196
10:02 ET6830814.15
10:04 ET8345114.285
10:06 ET22398714.59
10:08 ET21359014.65
10:09 ET14282414.75
10:11 ET11921814.75
10:13 ET10167314.77
10:15 ET5994714.6999
10:18 ET3962414.6512
10:20 ET7037914.745
10:22 ET9870514.67
10:24 ET5256914.655
10:26 ET9156614.68
10:27 ET14145414.31
10:29 ET14645014.24
10:31 ET6512514.1351
10:33 ET6549414.1984
10:36 ET8301614.3033
10:38 ET5457614.15
10:40 ET4087414.01
10:42 ET4912714.18
10:44 ET5212214.26
10:45 ET6221114.2599
10:47 ET1599014.12
10:49 ET3250014.08
10:51 ET2394614.04
10:54 ET6833513.94
10:56 ET6031713.98
10:58 ET5190114.0264
11:00 ET4253914.08
11:02 ET3835514.21
11:03 ET3305214.07
11:05 ET1962913.94
11:07 ET4579513.94
11:09 ET4989313.845
11:12 ET2441213.81
11:14 ET4255613.7813
11:16 ET2333113.8151
11:18 ET4284213.8372
11:20 ET1586113.83
11:21 ET1344913.78
11:23 ET3605513.78
11:25 ET2463713.8112
11:27 ET4706114.0499
11:30 ET3017714.1091
11:32 ET2112614.0401
11:34 ET2494013.98
11:36 ET1852014.025
11:38 ET3334514.12
11:39 ET1196914.0526
11:41 ET1587914.095
11:43 ET3225314.0081
11:45 ET1893714.0412
11:48 ET3229914.04
11:50 ET1380714.02
11:52 ET1778313.94
11:54 ET5430214.072
11:56 ET3758214.04
11:57 ET5757514.166
11:59 ET3243614.2118
12:01 ET2282314.1778
12:03 ET4018714.03
12:06 ET1954113.9424
12:08 ET2542613.8701
12:10 ET7086613.81
12:12 ET3441613.8
12:14 ET3224513.74
12:15 ET3138113.7336
12:17 ET3435213.8
12:19 ET1554413.79
12:21 ET1642813.78
12:24 ET1600113.7127
12:26 ET1595813.76
12:28 ET1237813.7446
12:30 ET2982813.7093
12:32 ET8993713.5957
12:33 ET4502113.5616
12:35 ET8721913.56
12:37 ET2640913.5803
12:39 ET1456113.52
12:42 ET2452413.5036
12:44 ET4245913.5
12:46 ET5832713.43
12:48 ET1976813.45
12:50 ET1466213.47
12:51 ET4689313.325
12:53 ET3702413.32
12:55 ET1966213.408
12:57 ET2856713.318
01:00 ET9669013.2001
01:02 ET4108013.331
01:04 ET702813.3599
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALT
Altimmune Inc
742.0M
-8.5x
---
United StatesELVN
Enliven Therapeutics Inc
728.6M
5.6x
+33.43%
United StatesOLMA
Olema Pharmaceuticals Inc
755.9M
-5.6x
---
United StatesCMPS
Compass Pathways PLC
724.8M
-4.7x
---
United StatesATXS
Astria Therapeutics Inc
764.2M
-6.5x
---
United StatesSVRA
Savara Inc
717.3M
-16.1x
---
As of 2024-02-28

Company Information

Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and is in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany Spain and Thailand. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Contact Information

Headquarters
910 Clopper Rd Ste 201SGAITHERSBURG, MD, United States 20878-1361
Phone
240-654-1450
Fax
302-674-5266

Executives

Chairman of the Board
Mitchel Sayare
President, Chief Executive Officer, Director
Vipin Garg
Chief Financial Officer
Richard Eisenstadt
Chief Scientific Officer
M. Scot Roberts
Chief Medical Officer
M. Scott Harris

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$742.0M
Revenue (TTM)
$279.0K
Shares Outstanding
53.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.11
EPS
$-1.57
Book Value
$3.77
P/E Ratio
-8.5x
Price/Sales (TTM)
2,659.5
Price/Cash Flow (TTM)
---
Operating Margin
-30,609.32%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.